New York 2025 Session Status: Introduced

A9010 — Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

Last action — In Assembly Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Assembly. Introduced August 13, 2025. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The bill requires discussions about risks before prescribing certain controlled substances.

This bill mandates that healthcare practitioners discuss specific risks with patients receiving schedule II controlled substances or opioid analgesics. The Department of Health will develop guidelines for practitioners regarding these discussions.

What this means for you
  • Healthcare: Practitioners must engage patients in discussions about risks when prescribing certain medications.

Summary

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Bill Text

How this bill changes current law

1 change Share ↗

Compared against the New York Consolidated Laws as published AI-generated reading aid — verify against the official bill.

This bill amends 1 section(s) of the New York Consolidated Laws: Section 3331 of the public health law.

  • Section 3331 of the public health law

    neuromusculoskeletal an opioid treatment With to a particular patient an opioid of each → prescription of any opioid drug which is an initial prescription for acute or chronic pain and again prior to issuing the third prescription of the course of treatment as set forth in paragraph (b) of this subdivision italics A practitioner shall discuss with the patient, or the patient's parent or guardian if the patient is under eighteen years of age and is not an emancipated minor, the risks associated with the drugs being prescribed, including but not limited to: (i) the risks of addiction and overdose associated with opioid drugs and the dangers of taking opioid drugs with alcohol, benzodiazepines and other central nervous system depressants; (ii) the reasons why the prescription is necessary; (iii) alternative treatments that may be available; and (iv) the risks associated with the use of the drugs being prescribed, specifically that opioids are highly addictive, even when taken as prescribed, that there is a risk of developing a physical or psycholog- ical dependence on the controlled substance, and that the risks of taking more opioids than prescribed, or mixing sedatives, benzodiaze- pines or alcohol with opioids, can result in fatal respiratory depression. (c) The department shall develop and make available to practitioners guidelines for the discussion required by this subdivision. (d) (vii) "Opioid analgesics" means the medicines buprenorphine, butorpha- nol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene as well as their brand names, isomers and combinations. For opioid analgesic a calendar that is greater than a one week's supply, counsel the patient on the risks of overdose, and

    amended

Action History

  1. PRINT NUMBER 9010B

  2. AMEND AND RECOMMIT TO HEALTH

  3. PRINT NUMBER 9010A

  4. AMEND AND RECOMMIT TO HEALTH

  5. REFERRED TO HEALTH

  6. REFERRED TO HEALTH

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does A9010 do?
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Who sponsors A9010?
A9010 is sponsored by Linda Rosenthal.
What is the current status of A9010?
This bill has been introduced in the Assembly. Introduced August 13, 2025. It must pass committee before a floor vote.
Where can I track A9010?
Track A9010 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on A9010

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of A9010

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →